A
Alite
Offers IT outsourcing, web development, and web hosting services
About Alite
Founded in 2005, Alite (also known as Alite Life Sciences or 艾力特国际贸易有限公司) has established itself as a key supplier of laboratory instruments and equipment within China's life science and biotechnology sectors. The company is headquartered in Shanghai, where its R&D center is also located, and has expanded its presence with offices in Beijing, Guangzhou, Chengdu, and Europe.
Alite's business model centers on a dual approach: it develops its own proprietary products, such as the CountStar cell analyzer, while also acting as a Chinese partner for numerous European and American biological equipment suppliers. This strategy allows the company to offer a comprehensive range of products, from laboratory instruments and testing reagents to production equipment, catering to the entire lifecycle from research and development to full-scale production. Revenue is generated through the sale of these products and the provision of related technical services.
The company serves a diverse client base, primarily consisting of leading biopharmaceutical, cell therapy, and biotechnology companies in China. It also supplies equipment to a large number of basic life sciences research institutions and government laboratories. Alite provides solutions for various applications, including CAR-T, stem cell therapy, vaccines, and antibodies. The firm has obtained multiple invention patents in China, the United States, and Japan.
As a distributor, Alite offers an extensive portfolio of products from international partners. This includes stability test chambers and incubators from Germany's MMM Group, online live cell analyzers from the UK's ABER, and cell growth factors and ELISA kits from the US-based Repligen, among others. In addition to equipment sales, Alite provides professional space sterilization services for clients who require sterilization for facilities ranging from small labs to large buildings but may not own the necessary equipment.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2022 | $14M | $55M | Zhengxingu Capital · Yida Capital | ↗ |
Growth signals
Latest recorded traffic for Alite is 630 monthly website visits, down 42.7% over the last three months. Alite's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- ZCZhengxingu Capital
- YCYida Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alite on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alite’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.